Supplemental Digital Content is Available in the Text.This prospective study demonstrated significant visual and anatomical improvements after sustained biweekly (every 2 weeks) aflibercept in patients with refractory subretinal fluid secondary to neovascular age-related macular degeneration despite prior chronic monthly dosing.